Literature DB >> 9421101

Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy.

D Battino1, D Croci, T Granata, M Estienne, F Pisani, G Avanzini.   

Abstract

The effects of age and concomitant treatment on plasma lamotrigine (LTG) concentration/dose (C/D) ratios were retrospectively evaluated on 482 consecutive routine LTG determinations from 106 chronically-treated patients with epilepsy (40 children and adolescents aged younger than 16 years, and 66 adults aged 17 to 62 years). A linear dose/level relationship was observed in individual patients but not in the cumulative analysis, which failed to show any correlation between the administered LTG dose and plasma concentrations. In the adult group, there were no correlations between the administered LTG dose and plasma concentrations. Associated antiepileptic therapy affected the LTG concentration/dose ratio, which was significantly higher in the patients receiving valproic acid (3.4 +/- 2.0, n = 23) and significantly lower in those treated with enzyme-inducing antiepileptic drugs (0.6 +/- 0.5, n = 57) than in the patients receiving valproic acid in combination with enzyme-inducing antiepileptic drugs, ethosuximide, vigabatrin, or clobazam (1.9 +/- 1.6, n = 26). The LTG C/D ratios significantly increased with increasing plasma valproic acid concentrations, and significantly decreased with increasing phenytoin concentrations. The effect of enzyme-inducing antiepileptic drugs increased with the number of associated drugs. A clear age effect was demonstrated in the homogeneously treated subgroups, in all of which adults had higher C/D ratios than children.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9421101     DOI: 10.1097/00007691-199712000-00003

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

1.  Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring.

Authors:  A M Almeida; A C Falcão; F Sales; I Baldeiras; M J Rocha; M M Caramona
Journal:  Eur J Clin Pharmacol       Date:  2006-07-27       Impact factor: 2.953

2.  Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service.

Authors:  R G Morris; A B Black; A L Harris; A B Batty; B C Sallustio
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

Review 3.  Lamotrigine. A review of its use in childhood epilepsy.

Authors:  C R Culy; K L Goa
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.022

Review 4.  Molecular and therapeutic potential and toxicity of valproic acid.

Authors:  Sébastien Chateauvieux; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  J Biomed Biotechnol       Date:  2010-07-29

5.  Lamotrigine and valproate pharmacokinetics interactions in epileptic patients.

Authors:  Mladena Lalic; Jelena Cvejic; Jovan Popovic; Ksenija Bozic; Svetlana Golocorbin-Kon; Hani Al-Salami; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Apr-Jun       Impact factor: 2.441

Review 6.  Antiepileptic drugs in the treatment of neuropathic pain.

Authors:  Elon Eisenberg; Yaron River; Ala Shifrin; Norberto Krivoy
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

8.  Lamotrigine in children and adolescents: the impact of age on its serum concentrations and on the extent of drug interactions.

Authors:  Arne Reimers; Eirik Skogvoll; Janne Kutschera Sund; Olav Spigset
Journal:  Eur J Clin Pharmacol       Date:  2007-05-12       Impact factor: 3.064

9.  The influence of concomitant antiepileptic drugs on lamotrigine serum concentrations in Northwest Chinese Han population with epilepsy.

Authors:  Xiaonian Han; Jing Huang; Jianhua Lv; Li Ma; Lirong Peng; Jinping Wang; Xiaojing Nie; Li Xia; Xin Zan
Journal:  PLoS One       Date:  2019-01-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.